NEW YORK and SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) — Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on the discovery and development of clinically differentiated small molecule therapeutics targeting pathways fundamental biology of cancers, today announced the appointment of Jan Skvarka, PhD, MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive who brings more than three decades of deep operational, strategic and financial expertise to Zentalis.
“We are delighted to welcome Jan, an experienced life sciences executive, to our Board of Directors,” said Dr. Kimberly Blackwell, President and CEO of Zentalis. “As a two-time CEO of clinical-stage companies, Jan has an extremely impressive track record of generating highly promising data, resetting and executing clinical priorities, and developing relationships with key players. Of the industry. Jan’s depth of experience will be invaluable as we advance the development of our potentially best-in-class lead candidates and create value for all of our stakeholders. »
Dr. Skvarka is currently Executive Chairman of GentiBio, Inc. and DEM BioPharma, Inc. Previously, he was President and Chief Executive Officer of Trillium Therapeutics, Inc., a publicly traded clinical-stage immuno-oncology company, where he led a highly successful 360-degree business transformation that produced a leading CD47 drug candidate, propelling Trillium from a $16 million market cap to a $2.3 billion acquisition by Pfizer Inc. In two years. Prior to Trillium, Dr. Skvarka served as President and CEO of Tal Medical, a private clinical-stage neuromodulation company, where he developed and executed the company’s strategy, built an accomplished management team, and oversaw its program. of clinical development. He has also held positions of increasing responsibility at Bain & Company, most recently as a partner, and was a senior member of the Bain Healthcare Practice, with a focus on life sciences. Dr. Skvarka holds a Bachelor of Business Administration and a Ph.D. in Economics from the University of Economics in Bratislava, Slovakia, and an MBA from Harvard Business School.
“I am delighted to join the passionate team of Zentalis at this pivotal moment in the company’s trajectory,” said Dr. Skvarka. “Zentalis has built a strong scientific base, and I believe its lead oncology candidates, ZN-c3 and ZN-d5, have broad therapeutic and commercial potential. I look forward to working with the leadership team as they execute the company’s strategic corporate and clinical goals to bring differentiated and transformational oncology therapies to patients.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics targeting fundamental cancer pathways. The company is developing a broad pipeline of potentially best-in-class oncology candidates, all discovered in-house, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company has licensed ZN-c3, ZN-d5 and ZN-c5 to its joint venture Zentera Therapeutics, Ltd., to develop and commercialize these candidates in China. Zentalis has operations in New York and San Diego.
For more information, visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to historical facts should be considered forward-looking statements, including , without limitation, statements regarding the progress of the clinical development of our product candidates; the potential impact of new members of our board of directors on our business, operations and financial results; the potential of our product candidates; and the execution of strategic objectives. The terms “expect”, “believe”, “expect”, “goals”, “plan”, “potential”, “will” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements. expressed or implied by the forward-looking statements. statements, including, but not limited to, the following: our limited operating history, which may make it difficult to assess our current business and predict our future success and viability; we have and expect to continue to incur material losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidates; the outcome of preclinical testing and early trials may not be predictive of the success of subsequent clinical trials; failure to identify additional product candidates and develop or commercialize marketable products; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain marketing authorization in the United States or abroad; our product candidates may cause serious adverse side effects; the inability to maintain our collaborations, or the failure of such collaborations; our dependence on third parties; the effects of significant competition; the possibility of system failures or security breaches; intellectual property risks; our ability to attract, retain and motivate qualified personnel, and the risks associated with managerial transitions; significant costs resulting from operating as a public company; the COVID-19 pandemic has had and may continue to have an adverse impact on our business, including our preclinical studies and clinical trials; and other important factors discussed under “Risk Factors” in our most recent periodic report filed on Form 10-K or 10-Q and subsequent filings with the United States Securities and Exchange Commission (SEC) and our other filings with the SEC. These forward-looking statements represent management’s estimates as of the date of this press release. Although we may choose to update these forward-looking statements at some time in the future, we disclaim any obligation to do so, even if subsequent events change our views.
ZENTALIS™ and its associated logos are registered trademarks of Zentalis and/or its subsidiaries. All website addresses and other links in this press release are for informational purposes only and are not intended to be an active link or to incorporate any website or other information in this press release.
Solebury Strategic Communications
Solebury Strategic Communications